Connection
Charles Edelstein to Hydroxymethylglutaryl-CoA Reductase Inhibitors
This is a "connection" page, showing publications Charles Edelstein has written about Hydroxymethylglutaryl-CoA Reductase Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.449 |
|
|
|
-
Keys DO, Edelstein CL. High-potency statins are associated with increased hospitalisations with acute kidney injury. Evid Based Med. 2014 Feb; 19(1):28.
Score: 0.292
-
Belibi FA, Edelstein CL. Novel targets for the treatment of autosomal dominant polycystic kidney disease. Expert Opin Investig Drugs. 2010 Mar; 19(3):315-28.
Score: 0.058
-
Edelstein CL. Therapeutic interventions for autosomal dominant polycystic kidney disease. Nephrol News Issues. 2008 Mar; 22(3):25-6.
Score: 0.051
-
Zafar I, Tao Y, Falk S, McFann K, Schrier RW, Edelstein CL. Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model. Am J Physiol Renal Physiol. 2007 Sep; 293(3):F854-9.
Score: 0.048